tiprankstipranks
Trending News
More News >
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA

IDEAYA Biosciences (IDYA) AI Stock Analysis

Compare
555 Followers

Top Page

ID

IDEAYA Biosciences

(NASDAQ:IDYA)

Rating:53Neutral
Price Target:
$21.50
▼(-1.06%Downside)
IDEAYA Biosciences' stock score is primarily impacted by its financial performance challenges, including declining revenues and net losses. Positive technical indicators provide some support, indicating potential short-term momentum. However, the lack of profitability and valuation concerns weigh heavily on the overall score.
Positive Factors
Clinical Results
Investors may be underappreciating the idea that median progression-free survival could meaningfully exceed the ~7 months observed in the single-arm Phase 2, indicating potential for better-than-expected clinical results.
Market Opportunity
Registry data suggest that the market opportunity for HLA-negative could be 3-4 times relative to HLA-positive, indicating a potentially larger market than previously expected.
Regulatory Approval
The company has aligned with the FDA on endpoints supportive of full approval for a pivotal neoadjuvant study in uveal melanoma.
Negative Factors
Approval Challenges
An accelerated approval opportunity, which the company previously highlighted as a possibility, is unlikely.
Data Disclosure
Investor focus on OS is unlikely to be fully addressed at the upcoming disclosure.
Market Uncertainty
Investors are understandably cautious on the de-risking potential of progression-free survival data on the overall survival full approval endpoint, indicating some uncertainty in the market.

IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)

IDEAYA Biosciences Business Overview & Revenue Model

Company DescriptionIDEAYA Biosciences, Inc. is a precision medicine oncology company dedicated to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates in the biotechnology and pharmaceutical sectors, focusing on synthetic lethality, an emerging field in cancer treatment, and direct targeting of oncogenic pathways. IDEAYA's core products and services include developing small molecule inhibitors and immuno-oncology therapies aimed at genetically defined cancer subsets.
How the Company Makes MoneyIDEAYA Biosciences generates revenue primarily through collaboration and license agreements with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments, and royalties on sales if the partnered drugs successfully reach the market. For instance, IDEAYA may collaborate with larger pharmaceutical companies to co-develop and commercialize its drug candidates, leveraging their partner's resources and expertise in exchange for shared financial benefits. The company's revenue is also supported by research grants and funding aimed at advancing its pipeline of potential cancer therapies. However, as a clinical-stage biotech company, significant revenue generation is generally contingent on the successful development, approval, and commercialization of its drug candidates.

IDEAYA Biosciences Financial Statement Overview

Summary
IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.
Income Statement
42
Neutral
The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.
Balance Sheet
55
Neutral
IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.
Cash Flow
48
Neutral
Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
7.00M23.39M50.93M27.94M19.54M
Gross Profit
7.00M19.38M48.83M26.22M-20.16M
EBIT
-326.98M-134.43M-62.50M-50.27M-35.34M
EBITDA
-326.98M-130.42M-60.40M-48.54M-33.96M
Net Income Common Stockholders
-274.48M-112.96M-54.81M-47.53M-32.27M
Balance SheetCash, Cash Equivalents and Short-Term Investments
676.32M525.11M373.15M368.06M283.58M
Total Assets
1.12B649.32M387.97M381.35M298.27M
Total Debt
19.17M2.87M3.48M5.18M6.72M
Net Debt
-65.21M-154.15M-65.15M-86.86M-65.31M
Total Liabilities
64.94M28.23M387.97M381.35M298.27M
Stockholders Equity
1.06B621.09M349.45M301.51M198.27M
Cash FlowFree Cash Flow
-251.44M-117.59M-90.62M-58.42M54.97M
Operating Cash Flow
-247.58M-115.22M-87.17M-55.78M55.46M
Investing Cash Flow
-502.56M-158.46M-33.40M-69.67M-146.24M
Financing Cash Flow
677.55M362.72M97.17M145.45M128.75M

IDEAYA Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price21.73
Price Trends
50DMA
18.33
Positive
100DMA
19.64
Positive
200DMA
24.94
Negative
Market Momentum
MACD
0.87
Negative
RSI
65.61
Neutral
STOCH
79.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 21.73 is above the 20-day moving average (MA) of 19.49, above the 50-day MA of 18.33, and below the 200-day MA of 24.94, indicating a neutral trend. The MACD of 0.87 indicates Negative momentum. The RSI at 65.61 is Neutral, neither overbought nor oversold. The STOCH value of 79.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Risk Analysis

IDEAYA Biosciences disclosed 77 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IDEAYA Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$1.87B-5.78%25.50%64.63%
61
Neutral
$3.10B-32.17%-25.85%-23.89%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
53
Neutral
$1.90B-31.34%-54.85%-79.25%
49
Neutral
$1.87B-38.04%-82.38%-164.76%
49
Neutral
$2.05B-16.57%
42
Neutral
$1.50B-69.30%-68.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDYA
IDEAYA Biosciences
21.71
-15.87
-42.23%
ETNB
89bio
10.57
1.89
21.77%
BEAM
Beam Therapeutics
18.17
-6.69
-26.91%
KYMR
Kymera Therapeutics
47.16
12.59
36.42%
IMCR
Immunocore Holdings
36.07
-5.03
-12.24%
CGON
CG Oncology, Inc.
27.00
-8.20
-23.30%

IDEAYA Biosciences Corporate Events

Executive/Board ChangesShareholder Meetings
IDEAYA Biosciences Announces Board Restructuring Plans
Neutral
Apr 2, 2025

On March 28, 2025, Susan L. Kelley, M.D. notified IDEAYA Biosciences of her decision not to seek re-election to the Board of Directors at the 2025 annual meeting of stockholders. Dr. Kelley will resign from the Board at the end of her current term but will transition to an advisory role as Chair of the new Clinical Advisory Board. The company plans to reduce the Board size to seven directors after the meeting, and Dr. Kelley’s decision is not due to any disagreement with the company’s operations or policies.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.